John Strickler

Jan 13, 2025 | onclive.com | John Strickler

“[Gastroesophageal cancer] is a disease entity with a significant unmet need where patients still have fairly short survival times. Therefore, it’s important for us to bring in new classes of therapies to try to improve both quality of life and length of life.”John H.

Jan 6, 2025 | onclive.com | John Strickler

CommentaryVideoJanuary 6, 2025Author(s):John H. Strickler, MD, discusses the rationale for developing telisotuzumab adizutecan in MET gene–amplified advanced gastric cancer. “We know that c-Met overexpression is common in many gastroesophageal cancers. Because this appears to be a relevant target, it would be natural to consider an antibody-drug conjugate that can use that c-Met expression as an entry point into the cell, thereby delivering that toxic payload.”John H.

Dec 2, 2024 | onclive.com | John Strickler

CommentaryPodcastDecember 2, 2024Author(s):Fact checked by:,Dr Strickler discusses the challenges of targeting RAS alterations in pancreatic cancer and efforts to improve pancreatic cancer screening rates. Welcome to OncLive On Air®! I’m your host today, Chris Ryan. OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care.

Nov 21, 2024 | onclive.com | John Strickler

CommentaryVideoNovember 21, 2024Supplements and Featured PublicationsPancreatic Cancer Awareness Month: Updates in Ongoing Research in RAS InhibitionVolume1 Issue 1Author(s):John H. Strickler, MD, discusses the role of biomarker testing in metastatic pancreatic cancer. Biomarker testing is now critical for the management of all advanced solid tumors, more or less.

Oct 12, 2024 | targetedonc.com | John Strickler

ABBV-400 is a novel antibody-drug conjugate (ADC) targeting the c-Met protein, which is overexpressed in several cancers, including gastroesophageal junction (GEJ) adenocarcinoma. This ADC is being investigated in a phase 1 clinical trial (NCT05029882) for patients with advanced solid tumors. Patients with advanced GEJ cancer who had progressed after receiving up to 2 prior lines of chemotherapy were treated with ABBV-400 at a dose of 3.0 mg/kg every three weeks.